RINVOQ can be taken as monotherapy or in combination with methotrexate. Consistent responses were observed alone or in combination with methotrexate for primary and key secondary endpoints.1
Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.
- RINVOQ SmPC.
UK-UPAD-230037. Date of preparation: March 2023
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]